Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 4/20 | 0.45 |
| ▸ | RAMP3 | O60896 | 12/20 | 0.43 |
| ▸ | CALCR | P30988 | 12/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30868635 | 1.00 | KEAP1 (0.45) | KEAP1RAMP3CALCREPHA2CXCR4 | |
| SCHEMBL30868651 | 0.98 | KEAP1 (0.44) | KEAP1RAMP3CALCREPHA2CXCR4 | |
| SCHEMBL14028315 | 0.95 | RAMP3 (0.46) | KEAP1RAMP3CALCR | |
| SCHEMBL30868640 | 0.95 | NMUR2 (0.44) | KEAP1RAMP3CALCRCXCR4 | |
| SCHEMBL30957280 | 0.93 | RAMP3 (0.46) | KEAP1RAMP3CALCR | |
| SCHEMBL30868648 | 0.93 | IL23R (0.43) | RAMP3CALCRCXCR4 | |
| SCHEMBL30957282 | 0.93 | EPHA2 (0.49) | RAMP3CALCREPHA2CXCR4 | |
| Risuteganib SCHEMBL13827707 | 0.91 | RAMP3 (0.42) | KEAP1RAMP3CALCR | |
| Risuteganib SCHEMBL19410625 | 0.91 | RAMP3 (0.42) | KEAP1RAMP3CALCR | |
| Risuteganib SCHEMBL22589325 | 0.91 | RAMP3 (0.42) | KEAP1RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718687-B2 | Biomoletron for regulation stem cell differentiation | SOGANGN UNIVERSITY RESEARCH FOUNDATION (KR) | 2023-08-08 | — | — | US | claimed |
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023191209-A1 | MICELLE INCLUDING HYDROPHILIC PEPTIDE AND USE THEREOF | 주식회사 퓨전바이오텍 | 2023-10-05 | — | — | WO | disclosed |
| US-11752180-B2 | Intestinal protectant | NATIONAL UNIVERSITY CORPORATION ASAHIKAWA MEDICAL UNIVERSITY (JP) | 2023-09-12 | — | — | US | disclosed |
| CN-111494642-B | Self-assembly material for in-situ construction of artificial extracellular matrix and preparation method and application thereof | 国家纳米科学中心 | 2022-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752180-B2 | Intestinal protectant | FABP2, SI, SLC10A2 | KEAP1 894/4885RAMP3 3355/4885CALCR 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.